• Japanese
  • Korean
  • Chinese
Cover Image

Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Abstract

Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Supraventricular Tachycardia (SVT) Therapeutics market. The report identifies the key trends shaping and driving the global Supraventricular Tachycardia (SVT) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Supraventricular Tachycardia (SVT) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Supraventricular Tachycardia (SVT) Therapeutics market. Its scope includes -

  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Supraventricular Tachycardia (SVT) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
  • Analysis of the current and future competition in the seven key countries Supraventricular Tachycardia (SVT) Therapeutics market.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Supraventricular Tachycardia (SVT) Therapeutics market.
  • Analysis of key recent licensing and partnership agreements in Supraventricular Tachycardia (SVT) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Supraventricular Tachycardia (SVT) Therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Supraventricular Tachycardia (SVT) Therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What's the next big thing in the global Supraventricular Tachycardia (SVT) Therapeutics market landscape? - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 3

  • 1.1 List of Tables 5
  • 1.2 List of Figures 6

2 Supraventricular Tachycardia (SVT) Therapeutics - Introduction 7

  • 2.1 Overview 7
  • 2.2 Epidemiology 10
    • 2.2.1 Historic Epidemiology (2006-2011) 10
    • 2.2.2 Forecast Epidemiology (2011-2019) 11
  • 2.3 Prognosis 12
  • 2.4 Etiology 12
  • 2.5 Signs and Symptoms 12
  • 2.6 Diagnosis 13
  • 2.7 Pathophysiology 14
  • 2.8 Treatment and Management Pattern 15
  • 2.9 Referral Pathway 17
  • 2.10 GlobalData Pipeline Report Guidance 18

3 SVT Therapeutics - Market Characterization 19

  • 3.1 SVT Therapeutics Market Size (2006-2011) - Global 19
  • 3.2 SVT Therapeutics Market Forecast (2011-2019) - Global 21
  • 3.3 SVT Therapeutics Market Size (2006-2011) - The US 23
  • 3.4 SVT Therapeutics Market Forecast (2011-2019) - The US 24
  • 3.5 SVT Therapeutics Market Size (2006-2011) - France 25
  • 3.6 SVT Therapeutics Market Forecast (2011-2019) - France 26
  • 3.7 SVT Therapeutics Market Size (2006-2011) - Germany 27
  • 3.8 SVT Therapeutics Market Forecast (2011-2019) - Germany 28
  • 3.9 SVT Therapeutics Market Size (2006-2011) - Italy 29
  • 3.10 SVT Therapeutics Market Forecast (2011-2019) - Italy 30
  • 3.11 SVT Therapeutics Market Size (2006-2011) - Spain 31
  • 3.12 SVT Therapeutics Market Forecast (2011-2019) - Spain 32
  • 3.13 SVT Therapeutics Market Size (2006-2011) - The UK 33
  • 3.14 SVT Therapeutics Market Forecast (2011-2019) - The UK 34
  • 3.15 SVT Therapeutics Market Size (2006-2011) - Japan 35
  • 3.16 SVT Therapeutics Market Forecast (2011-2019) - Japan 36
  • 3.17 Drivers and Barriers for the SVT Therapeutics Market 37
    • 3.17.1 Drivers for the SVT Therapeutics Market 37
    • 3.17.2 Barriers for the SVT Therapeutics Market 37
  • 3.18 Opportunity and Unmet Need 39
  • 3.19 Key Takeaway 40

4 SVT Therapeutics - Competitive Assessment 41

  • 4.1 Overview 41
  • 4.2 Strategic Competitor Assessment 41
  • 4.3 Product Profile for Major Marketed Products in the SVT Therapeutics Market 42
    • 4.3.1 Multaq (Dronedarone) 42
    • 4.3.2 Pradaxa (dabigatran etexilate mesylate) 43
    • 4.3.3 Adenocard (adenosine) 45
    • 4.3.4 Xarelto (rivaroxaban) 45
    • 4.3.5 Calcium channel blocker (Ca channel blocker) 46
    • 4.3.6 Beta blocker 47
  • 4.4 Key Takeaway 47

5 SVT Therapeutics - Pipeline Assessment 48

  • 5.1 Overview 48
  • 5.2 Strategic Pipeline Assessment 48
  • 5.3 SVT- Pipeline Analysis by Phase of Development 49
    • 5.3.1 SVT- Phase III Pipeline 49
    • 5.3.2 SVT- Phase II Pipeline 49
    • 5.3.3 SVT- Phase I Pipeline 50
    • 5.3.4 SVT- Preclinical Pipeline 50
    • 5.3.5 SVT- Discovery Pipeline 50
  • 5.4 SVT- Pipeline by Mechanism of Action 51
  • 5.5 Technology Trends Analytical Framework 53
  • 5.6 Most Promising Drug Profiles 54
    • 5.6.1 Eliquis (apixaban) 54
    • 5.6.2 Brinavess (vernakalant) 55
    • 5.6.3 Edoxaban (DU-176b) 56
    • 5.6.4 Gencaro 57
  • 5.7 Key Takeaway 58

6 SVT Therapeutics - Clinical Trials Mapping 59

  • 6.1 Clinical Trials by Region and Country 59
  • 6.2 Clinical Trials by Phase of Clinical Development 60
  • 6.3 Clinical Trials by Trial Status 61
  • 6.4 Clinical Trials by Sponsors 62
  • 6.5 Top Companies Participating in SVT Clinical Trials 65

7 SVT Therapeutics - Strategic Assessment 67

  • 7.1 Key Events Impacting the Future Market 67
  • 7.2 Future Market Competition Scenario 68

8 SVT Therapeutics - Future Players 70

  • 8.1 Introduction 70
  • 8.2 Company Profiles 71
    • 8.2.1 Pfizer 71
    • 8.2.2 Bristol-Myers Squibb 72
    • 8.2.3 Cardiome Pharma 72
    • 8.2.4 Daiichi Sankyo Inc. 73
    • 8.2.5 ARCA biopharma 75
    • 8.2.6 Sanofi 75
    • 8.2.7 Boehringer Ingelheim 77
    • 8.2.8 Bayer HealthCare 78
  • 8.3 Details of Other Companies in the Pipeline 79

9 SVT Therapeutics - Licensing and Partnership Deals 81

10 SVT Therapeutics - Appendix 82

  • 10.1 Definitions 82
  • 10.2 Acronyms 82
  • 10.3 Bibliography 83
  • 10.4 Physicians and Specialists Included in this Study 84
  • 10.5 Research Methodology 84
    • 10.5.1 Coverage 84
    • 10.5.2 Secondary Research 85
    • 10.5.3 Forecasting 85
    • 10.5.4 Primary Research 88
    • 10.5.5 Expert Panel Validation 88
  • 10.6 Contact Us 88
  • 10.7 Disclaimer 88

List of Tables

1.1 List of Tables

  • Table 1: Historic Epidemiology, Prevalent Population, 2006-2011 10
  • Table 2: Forecast Epidemiology, Prevalent Population, 2011-2019 11
  • Table 3: SVT Therapeutics Market, Global, Revenue ($m), 2006-2011 20
  • Table 4: SVT Therapeutics Market, Global, Forecast ($m), 2011-2019 22
  • Table 5: SVT Therapeutics Market, US, Revenue ($m), 2006-2011 23
  • Table 6: SVT Therapeutics Market, US, Forecast ($m), 2011-2019 24
  • Table 7: SVT Therapeutics Market, France, Revenue ($m), 2006-2011 25
  • Table 8: SVT Therapeutics Market, France, Forecast ($m), 2011-2019 26
  • Table 9: SVT Therapeutics Market, Germany, Revenue ($m), 2006-2011 27
  • Table 10: SVT Therapeutics Market, Germany, Forecast ($m), 2011-2019 28
  • Table 11: SVT Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
  • Table 12: SVT Therapeutics Market, Italy, Forecast ($m), 2011-2019 30
  • Table 13: SVT Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
  • Table 14: SVT Therapeutics Market, Spain, Forecast ($m), 2011-2019 32
  • Table 15: SVT Therapeutics Market, UK, Revenue ($m), 2006-2011 33
  • Table 16: SVT Therapeutics Market, UK, Forecast ($m), 2011-2019 34
  • Table 17: SVT Therapeutics Market, Japan, Revenue ($m), 2006-2011 35
  • Table 18: SVT Therapeutics Market, Japan, Forecast ($m), 2011-2019 36
  • Table 19: SVT Therapeutics - Drug Information 47
  • Table 20: SVT Therapeutics - Phase III/Filed Pipeline, 2011 49
  • Table 21: SVT Therapeutics - Phase II Pipeline, 2011 49
  • Table 22: SVT Therapeutics - Phase I Pipeline, 2011 50
  • Table 23: SVT Therapeutics - Preclinical Pipeline, 2011 50
  • Table 24: SVT Therapeutics - Discovery Pipeline, 2011 50
  • Table 25: Development Status of Eliquis 55
  • Table 26: Development Status of Brinavess 56
  • Table 27: Development Status of Edoxaban 57
  • Table 28: Development Status of Gencaro 58
  • Table 29: SVT Therapeutics, Global, Clinical Trials, 2011 59
  • Table 30: SVT Therapeutics, Global, Clinical Trials by Phase, 2011 60
  • Table 31: SVT Therapeutics, Global, Clinical Trials by Status of Development, 2011 61
  • Table 32: SVT Therapeutics, Global, Overall Sponsors, 2011 62
  • Table 33: SVT Therapeutics, Global, Prominent Sponsors, 2011 64
  • Table 34: SVT Therapeutics, Global, Top Ten Companies by Phase, 2011 66
  • Table 35: Pfizer - SVT Pipeline, 2011 71
  • Table 36: Bristol-Myers Squibb - SVT Pipeline, 2011 72
  • Table 37: Cardiome Pharma - SVT Pipeline, 2011 73
  • Table 38: Daiichi Sankyo - SVT Pipeline, 2011 74
  • Table 39: ARCA Biopharma - SVT Pipeline, 2011 75
  • Table 40: Sanofi - SVT Marketed Drug, 2011 77
  • Table 41: Boehringer Ingelheim - SVT Marketed Drug, 2011 78
  • Table 42: Bayer - SVT Marketed Drug, 2011 78
  • Table 43: Description of Other Companies in the Pipeline, 2011 79
  • Table 44: SVT Therapeutics, Licensing and Partnership Deals, 2011 81

List of Figures

1.2 List of Figures

  • Figure 1: Various Origins of SVT 9
  • Figure 2: Tachycardia Classification 9
  • Figure 3: SVT Therapeutics - Treatment Flow Analysis 11
  • Figure 4: Supraventricular Tachycardia ECG Recordings and Diagnosis 13
  • Figure 5: SVT Co-morbidities, Symptoms and ECG Findings 14
  • Figure 6: SVT Therapeutics - Treatment Algorithm 16
  • Figure 7: SVT Therapeutics - Referral Pathway 17
  • Figure 8: SVT Therapeutics Market, Global, Revenue ($m), 2006-2011 19
  • Figure 9: SVT Therapeutics Market, Global, Forecast ($m), 2011-2019 21
  • Figure 10: SVT Therapeutics Market, US, Revenue ($m), 2006-2011 23
  • Figure 11: SVT Therapeutics Market, US, Forecast ($m), 2011-2019 24
  • Figure 12: SVT Therapeutics Market, France, Revenue ($m), 2006-2011 25
  • Figure 13: SVT Therapeutics Market, France, Forecast ($m), 2011-2019 26
  • Figure 14: SVT Therapeutics Market, Germany , Revenue ($m), 2006-2011 27
  • Figure 15: SVT Therapeutics Market, Germany, Forecast ($m), 2011-2019 28
  • Figure 16: SVT Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
  • Figure 17: SVT Therapeutics Market, Italy, Forecast ($m), 2011-2019 30
  • Figure 18: SVT Therapeutics Market, Spain, Revenue ($m), 2006-2011 31
  • Figure 19: SVT Therapeutics Market, Spain, Forecast ($m), 2011-2019 32
  • Figure 20: SVT Therapeutics Market, UK, Revenue ($m), 2006-2011 33
  • Figure 21: SVT Therapeutics Market, UK, Forecast ($m), 2011-2019 34
  • Figure 22: SVT Therapeutics Market, Japan, Revenue ($m), 2006-2011 35
  • Figure 23: SVT Therapeutics Market, Japan, Forecast ($m), 2011-2019 36
  • Figure 24: SVT Therapeutics Market, Drivers and Barriers, 2011 38
  • Figure 25: Opportunity and Unmet Need in the SVT Therapeutics Market, 2011 39
  • Figure 26: Strategic Competitor Assessment of the Marketed Products in SVT Therapeutics, 2011 41
  • Figure 27: SVT Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 51
  • Figure 28: SVT Therapeutics, Clinical Pipeline by Drug Class (%), 2011 52
  • Figure 29: SVT- Clinical Pipeline by Phase of Development (%), 2011 52
  • Figure 30: Technology Trends Analytics Framework, 2011 53
  • Figure 31: Technology Trends Analytics Framework - Description, 2011 54
  • Figure 32: SVT Therapeutics, Global, Clinical Trials by Country, 2011 59
  • Figure 33: SVT Therapeutics, Global, Clinical Trials by Phase (%), 2011 60
  • Figure 34: SVT Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 61
  • Figure 35: SVT Therapeutics, Global, Overall Sponsors (%), 2011 62
  • Figure 36: SVT Therapeutics, Global, Prominent Sponsors (%), 2011 63
  • Figure 37: SVT Therapeutics, Global, Top Companies by Phase, 2011 65
  • Figure 38: SVT Therapeutics Market, Drivers and Barriers, 2011 67
  • Figure 39: Implications for Future Market Competition in the SVT Therapeutics Market, 2011 68
  • Figure 40: SVT Therapeutics, Clinical Pipeline by Company, 2011 70
  • Figure 41: GlobalData Market Forecasting Model 87
Show More
Pricing
Get Notified
Email me when related reports are published